BTG granted approval in China for liver cancer treatment
BTG
840.00p
16:30 16/08/19
FTSE 250
19,273.58
10:10 19/04/24
FTSE 350
4,303.52
10:10 19/04/24
FTSE All-Share
4,260.00
10:10 19/04/24
Pharmaceuticals & Biotechnology
20,945.57
10:09 19/04/24
Specialist healthcare company BTG and its partner SciClone Pharmaceuticals have received approval from the China Food and Drug Administration for the registration of its DC Bead treatment for a type of malignant liver tumour.
Following the approval, the partners have started planning the treatment's commercial launch. Under their agreement, US-based SciClone will purchase batches of the product from BTG at a specified price for sale in China.
Because of the country's high incidence of hepatitis, which is closely linked to liver cancer, China accounts for approximately one-half of the world's liver cancer cases.
DC Bead is currently approved in 40 countries worldwide, including in Europe. The treatment is an embolic bead delivered through a minimally invasive, non-surgical procedure to block the blood flow to tumours.
Chief executive officer at BTG, Louise Makin, said: "Approximately half of the world's liver cancer patients are in China and there is a great interest among Chinese physicians to offer new, differentiated treatment options.
"[This] news marks an important step toward bringing our first interventional oncology product, DC Bead, to the Chinese market where we can help address this need."
NR